Physician profile
Steven E Katz
NPI 1518906866
$256,210.32
in general payments reported to CMS, 2019-2025
31 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $15K · 2021: $24K · 2022: $51K · 2023: $65K · 2024: $47K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Honoraria: $44K · Food and Beverage: $12K · Consulting Fee: $12K · Travel and Lodging: $9,172 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,653.13 |
| Honoraria | $44,037.50 |
| Food and Beverage | $12,194.99 |
| Consulting Fee | $11,700.00 |
| Travel and Lodging | $9,172.19 |
| Education | $203.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124,997.51 | 2019-2023 | Tepezza |
| Amgen INC. | $77,413.91 | 2020-2025 | Tepezza |
| Abbvie INC. | $40,840.73 | 2021-2025 | |
| Argenx US, INC. | $5,142.32 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $1,292.38 | 2020-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $1,101.26 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $888.31 | 2019-2025 | Ultomiris, Soliris |
| Pfizer INC. | $719.76 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $525.61 | 2019-2022 | |
| Genentech USA, INC. | $504.07 | 2019-2025 | Enspryng, Actemra |
| Mallinckrodt Hospital Products INC. | $418.13 | 2023-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $378.31 | 2020-2025 | Cequa |
| Biohaven Pharmaceutical Holding Company Ltd. | $323.03 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $237.45 | 2021 | |
| Ani Pharmaceuticals, INC. | $176.91 | 2024-2025 | Purified Cortrophin Gel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $154.77 | 2020-2025 | Vyepti |
| Axsome Therapeutics, INC. | $137.62 | 2025 | Symbravo |
| Oyster Point Pharma, INC. | $134.11 | 2023-2025 | Tyrvaya, Ryzumvi |
| Depuy Synthes Sales INC. | $122.18 | 2020-2025 | Trumatch |
| Bausch & Lomb Americas INC. | $104.56 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Harrow Eye, LLC | $100.83 | 2024-2025 | Vevye |
| Alcon Vision LLC | $99.87 | 2022-2025 | Rocklatan, Tryptyr, Eysuvis |
| Impel Pharmaceuticals INC. | $95.02 | 2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $68.58 | 2020-2022 | |
| Merz Pharmaceuticals, LLC | $55.88 | 2024-2025 | Xeomin |
| Kala Pharmaceuticals, INC. | $43.39 | 2021 | |
| Impel Pharmaceuticals LLC | $42.31 | 2025 | Trudhesa |
| Springworks Therapeutics, INC. | $35.26 | 2025 | Gomekli |
| Catalyst Pharmaceuticals, INC. | $24.67 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.09 | 2025 | Entyvio |
| Thea Pharma INC. | $15.49 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.